::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

RISK OF PNEUMONIA IN OBSTRUCTIVE LUNG DISEASE

AUTHORS:

Hafiz M. Faheem Kamran, Dr. Dr. Salman Ahmad, Dr. Masooma Mushtaq

ABSTRACT:

Objectives of the study: The main objective of the study is to analyze the risk of pneumonia in obstructive lung disease. Methodology of the study: This cross-sectional study was conducted at Bahawal Victoria Hospital, Bahawalpur during March 2019 to December 2019. For this purpose, we select 100 patients of pneumonia for further analysis. The patients of both genders were selected for this study. Diagnosis of pneumonia: (i) unconfirmed i.e. all unique patients with codes for pneumonia and, (ii) confirmed by chest radiograph or resulting in hospitalization within one month of pneumonia diagnosis. Result: Significant differences were observed between patients who received extra-fine versus fine-particle COPD in the demographics and baseline characteristics, as shown in Table 1. The COPD treatments prescribed to patients before and at step-up are shown in S1 Table in the supporting information. Conclusion: In conclusion, the COPD exacerbation rate was higher among the patients who had a history of pneumonia or a high rate of COPD exacerbation in the preceding period of 1 year.